uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
| Revenue (TTM) | $18.67M |
| Gross Profit (TTM) | $-114.71M |
| EBITDA | $-182.92M |
| Operating Margin | -872.00% |
| Return on Equity | -157.60% |
| Return on Assets | -15.70% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $3.19 |
| Price-to-Book | 5.00 |
| Price-to-Sales (TTM) | 81.51 |
| EV/Revenue | 42.98 |
| EV/EBITDA | 1.40 |
| Quarterly Earnings Growth (YoY) | -18.20% |
| Quarterly Revenue Growth (YoY) | 11.00% |
| Shares Outstanding | $70.14M |
| Float | $57.52M |
| % Insiders | 1.26% |
| % Institutions | 98.07% |
Volatility is currently expanding
uniQure NASDAQ: QURE said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, and granted the application Priority Review with a target action date of May 1, 2027. The U.K. Medicines and Healthcare products Regulatory Agency has also validated the company's Marketing Authorization Application, according to management.
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
uniQure (QURE) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $1.38 per share a year ago.
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~
uniQure's stock has come under significant pressure again after the company reported mixed 4-year AMT-130 data. While measurement noise and control bias likely explain much of the disappointing results, there is now greater uncertainty around durability. I believe that uniQure's data is strong enough to support accelerated approval despite this, though.
~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world's first disease-modifying treatment for Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V.
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
uniQure (QURE) is rated a Speculative Buy with a $47 price target, implying 115% upside. QURE's Huntington's gene therapy BLA is under FDA accelerated review, with a decision expected around November 1. Three-year data met both FDA endpoints, showing 75% slowing of composite and 60% slowing of Total Functional Capacity.
New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QURE and any ticker you trade — then tracks every position and per-strategy win rate.
